NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
By Dr. Matthew Watson
TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange (“TSXV”). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone’s leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone’s strong market performance and strategic advances in the past year including 110% share price appreciation and 209% market cap growth.
Read the original here:
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
Related Post
- Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - February 20th, 2025
- NAYA Biosciences Announces Nomination of New Board Members - February 20th, 2025
- Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology - February 20th, 2025
- OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors - February 20th, 2025
- Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate - February 20th, 2025
- Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers - February 20th, 2025
- Better Choice Company Adjourns Special Meeting of Stockholders to March 21, 2025 - February 20th, 2025
- COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing - February 20th, 2025
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - February 20th, 2025
- GRI Bio Announces Reverse Stock Split - February 20th, 2025
- PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - February 20th, 2025
- ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March - February 20th, 2025
- Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock - February 20th, 2025
- Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - February 20th, 2025
- Zealand Pharma Announces Financial Results for the Full Year 2024 - February 20th, 2025
- argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 - February 20th, 2025
- EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform... - February 20th, 2025
- Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - February 20th, 2025
- Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders - February 20th, 2025
- Grace Therapeutics Announces Private Placement Financing of up to $30 Million - February 11th, 2025
- IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - February 11th, 2025
- Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience - February 11th, 2025
- Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - February 11th, 2025
- Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy - February 11th, 2025
- Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial - February 11th, 2025
- BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology /... - February 11th, 2025
- Capricor Therapeutics to Participate in Upcoming Investor Conferences - February 11th, 2025
- Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - February 11th, 2025
- Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - February 11th, 2025
- Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory... - February 11th, 2025
- Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - February 11th, 2025
- Revolo to Present at the 2025 AAAAI / WAO Joint Congress - February 11th, 2025
- Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - February 11th, 2025
- Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - February 11th, 2025
- Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 11th, 2025
- Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - February 11th, 2025
- LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - February 11th, 2025
- Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance - February 11th, 2025
- Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront - February 11th, 2025
- Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
- Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
- PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
- Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
- Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
- Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
- Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
- Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
- Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
- Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
- Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
- Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
- Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
- BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
- Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
- Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
- Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - January 31st, 2025
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
- Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - January 31st, 2025
- Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - January 31st, 2025
- Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
- Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 22nd, 2025
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 22nd, 2025
- Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 22nd, 2025
- Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 22nd, 2025
- Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 22nd, 2025
- Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31,... - January 22nd, 2025
- RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue - January 22nd, 2025
- Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - January 22nd, 2025
- Pharming Group to convene Extraordinary General Meeting of Shareholders - January 22nd, 2025
- BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders - January 22nd, 2025
- Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments - January 22nd, 2025
- Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd - January 22nd, 2025
- Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 - January 22nd, 2025
- NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director - January 22nd, 2025
- Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO... - January 22nd, 2025
- Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in... - January 22nd, 2025
- Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible... - January 22nd, 2025
- ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - January 22nd, 2025
- Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care - January 22nd, 2025
- Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
Global News Feed
Comments Off on NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock |
February 20th, 2025
This author published 6052 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research